IL13 and atopic eczema: Dupilumab, a dual-acting drug blocking both IL-4 and IL-13 function (Figure 1b) was approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2017 for use in atopic dermatitis.